The AI Multimodal Therapies company
Revolutionizing access to medicines with Multimodal Therapies (MMTs) empowered by AI for aging and age-related diseases with high unmet medical needs.
Tangramed, the science in progress
Tangramed Biotech is at the forefront of augmented drug polytherapy, combining multiple drugs to target complementary modes of action simultaneously.
Our approach integrates novel proprietary AI and experimental tools to address this complexity. Medicines with Multimodal Therapies (MMTs) rely on both existing and new drugs, representing a modern approach akin to recycling for new alloys.
​
Tangramed aspires to revolutionize access to medicines with MMTs powered by generative AI, targeting aging and age-related diseases with significant unmet medical needs (such as Alzheimer's disease, Age-related Macular Degeneration, glioblastoma...) while ensuring affordability for patients.
Generative AI has emerged as a beacon of hope in this field
However, relying solely on the current monotherapy or limited polytherapy paradigms may not be sufficient. Implementing standalone generative AI alongside the current paradigm may yield limited results, as the complexity of diseases remains a significant obstacle.
​
MMTs Innovation
Use AI to find MMTs targeting multiple complementary modes of action at once, robustly tackling disease complexity
Tangramed ambition
To overcome complexity, the Tangramed is switching to drug polytherapy by integrating proprietary AI and experimental tools.
Tangramed ambitions to revolutionize the access to medicines with augmented combinations empowered by AI for diseases with high unmet medical need.
Founders with solid track record
Tangramed was founded by a seasoned team of international renowned serial pioneers’ scientists and entrepreneurs, Pr. Daniel Cohen, and Dr. Jinchao Yu, with deep experience of Bio-AI, High Throughput drug screening, global R&D in Combinatorial Medicine, Business Development and US/Europe stock market listing.
The need and the gap filling solutions
The pharmaceutical industry and medicine face a multitude of challenges, including addressing complex diseases with substantial unmet needs such as Alzheimer's, cancer, and other age-related conditions.
​
Additionally, there is the ongoing challenge of managing the exorbitant expenses associated with new drug development, largely due to a staggering 90% failure rate.
​
Balancing progress and ethics while ensuring drug accessibility and affordability has become a global concern.
​
Mastering combinatorial treatments heralds a significant shift in the future, posing biological, clinical, and regulatory challenges. However, our 20 years of experience have equipped us to meet these challenges, particularly through the integration of artificial intelligence and innovative, cutting-edge experimental screening methods.
​
All supported by a remarkable international scientific advisory board.
Facts and figures
90%
Drug Development failure rate
50M
People with dementia worldwide in 2020
150M
People with dementia worldwide in 2050...
$1T
Alzheimer's healthcare cost in 2050 (USA only)
<2
Life expectancy with glioblastoma in years
Strategic partners
A unique dedicated translational triple platform
Adopting such an approach is exceptionally challenging and intricate. It necessitates the establishment of a dedicated translational triple platform:
​
-
Digital (Bio AI): This phase involves predicting a select set of augmented combinations from a vast pool of potential candidates for further testing.
-
Experimental: Once predicted combinations are identified, they undergo testing on diseased cells and animals to assess their viability.
-
Clinical: Finally, selected combinations proceed to clinical trials, where they are tested on patients, moving toward the proof-of-concept stage.
